PayPal Names Chriss CEO, Poaching Executive From Intuit
By Colin Kellaher
PayPal Holdings has tapped Intuit executive Alex Chriss as its next president and chief executive, ending a monthslong search for a new leader.
The San Jose, Calif., payments giant on Monday said Chriss will take the reins from Dan Schulman on Sept. 27 and also will join the board.
Chriss currently serves as executive vice president and general manager of Intuit's small business and self-employed group, which generates more than half of the TurboTax parent's revenue.
Intuit on Monday said its chief technology officer, Marianna Tessel, would succeed Chriss as general manager of the small business and self-employed group, effective Sept. 5, with Alex Balazs, currently chief technology architect, moving up to chief technology officer.
PayPal said Schulman, who in February announced plans to retire after nine years at the helm, will remain a member of the board until next May.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 14, 2023 09:54 ET (13:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track